RPG LifeScience.

Why is RPG Life Sciences Ltd falling/rising?

As of 12-Aug, RPG Life Sciences Ltd's stock price is declining, currently at 2,620.95, with a total drop of -10.53% over the last 12 days. Despite strong financial results and being net-debt free, negative market sentiment and reduced investor participation are contributing to the stock's downward trend.

As of 12-Aug, RPG Life Sciences Ltd is experiencing a decline in its stock price, currently at 2,620.95, reflecting a change of -7.4 (-0.28%). The stock has been underperforming, having fallen consecutively for the last 12 days, resulting in a total decline of -10.53% during this period. This trend is further highlighted by the stock's performance over the past week, where it has decreased by -3.29%, contrasting with the Sensex, which only fell by -0.78%.<BR><BR>Investor participation appears to be waning, as indicated by a significant drop in delivery volume, which fell by -27.15% compared to the 5-day average. Despite the stock being liquid enough for trading, the overall market sentiment seems negative, contributing to the downward pressure on the stock price.<BR><BR>While there are positive aspects such as the company being net-debt free and reporting strong financial results, including a highest PAT of Rs 30.76 cr and net sales of Rs 195.69 cr, these factors have not been sufficient to counteract the recent negative momentum in the stock price. The stock is also trading at a premium compared to its peers, which may deter some investors amidst the current decline. Overall, the combination of consecutive price falls, reduced investor participation, and underperformance relative to the sector are key reasons for the stock's current downward trajectory.

Which are the latest news on RPG LifeScience.?

Are RPG Life Sciences Ltd latest results good or bad?

RPG Life Sciences Ltd's latest Q1 FY27 results are positive, with a net profit of ₹30.76 crore (up 17% year-on-year) and revenue reaching ₹195.69 crore (up 15.85%). The company also improved its operating margin to 22.12% and achieved a return on equity of 20.40%, indicating strong operational performance and growth.

RPG Life Sciences Ltd's latest results for Q1 FY27 can be considered quite positive. The company reported a net profit of ₹30.76 crore, which reflects a year-on-year growth of 17%. Additionally, revenue grew by 15.85% compared to the same quarter last year, reaching an all-time high of ₹195.69 crore. This marks a sequential growth of 10.63% over the previous quarter, indicating strong momentum.<BR><BR>The operating margin improved to 22.12%, the highest in seven quarters, showcasing effective cost management and operational efficiency. Furthermore, the return on equity (ROE) stands at an impressive 20.40%, which is industry-leading.<BR><BR>Overall, the results highlight RPG Life Sciences' strengthening position in both domestic and export markets, supported by a diversified product portfolio. The company's ability to maintain double-digit revenue growth while expanding its operating margins signals a robust operational performance.

Should I buy, sell or hold RPG Life Sciences Ltd?

When is the next results date for RPG Life Sciences Ltd?

The next results date for RPG Life Sciences Ltd is July 28, 2026.

The next results date for RPG Life Sciences Ltd is scheduled for July 28, 2026.

How big is RPG LifeScience.?

As of 10th June, RPG Life Sciences Ltd has a market capitalization of 3,502.00 Cr and reported net sales of 681.69 Cr and net profit of 206.23 Cr over the latest four quarters. Shareholder's funds and total assets data are not available.

As of 10th June, <BR><BR>Market Cap: RPG Life Sciences Ltd has a market capitalization of 3,502.00 Cr and is classified as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 681.69 Cr, while the sum of Net Profit for the same period is 206.23 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is not specified, and the values for Shareholder's Funds and Total Assets are not available.

Who are in the management team of RPG LifeScience.?

The management team of RPG LifeScience includes Chairman H V Goenka, Managing Director C T Renganathan, and several Non-Executive Independent Directors, along with Company Secretary Rajesh Shirambekar, providing a blend of leadership and oversight.

The management team of RPG LifeScience includes the following individuals:<BR><BR>1. **H V Goenka** - Chairman<BR>2. **C T Renganathan** - Managing Director<BR>3. **C L Jain** - Non Executive Independent Director<BR>4. **Lalit S Kanodia** - Non Executive Independent Director<BR>5. **Mahesh S Gupta** - Non Executive Independent Director<BR>6. **Manoj K Maheshwari** - Non Executive Independent Director<BR>7. **Narendra Ambwani** - Non Executive Independent Director<BR>8. **Zahabiya Khorakiwala** - Non Executive Independent Director<BR>9. **Yugal Sikri** - Non Executive Independent Director<BR>10. **Sachin Nandgaonkar** - Non Executive Director<BR>11. **Rajesh Shirambekar** - Company Secretary<BR><BR>This team brings together a mix of leadership and independent oversight to guide the company.

Who are the peers of the RPG LifeScience.?

RPG LifeScience's peers include Advanced Enzyme, IOL Chemicals, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, Novartis India, Dishman Carbogen, Solara Active, and Morepen Labs. Most peers show Below Average growth and management risk, with IOL Chemicals having the highest 1-year return at 43.27%, while RPG LifeScience's return is 3.90%.

Peers: The peers of RPG LifeScience are Advanced Enzyme, IOL Chemicals, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, Novartis India, Dishman Carbogen, Solara Active, and Morepen Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Advanced Enzyme, IOL Chemicals, RPG LifeScience, and Novartis India, while Average management risk is found at Gufic BioScience, SMS Pharma, Aarti Drugs, and Morepen Labs. Below Average management risk is noted at Panacea Biotec, Dishman Carbogen, and Solara Active. All peers exhibit Below Average growth except for Novartis India, which has Good growth, while Advanced Enzyme, IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, and Morepen Labs show Below Average growth. Capital Structure is Excellent for Advanced Enzyme, IOL Chemicals, and Novartis India, Good for Aarti Drugs, Average for Gufic BioScience and SMS Pharma, and Below Average for Panacea Biotec, Dishman Carbogen, Solara Active, and Morepen Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is IOL Chemicals at 43.27%, while the lowest is Dishman Carbogen at -38.27%. RPG LifeScience's own 1-year return is 3.90%, which is higher than Dishman Carbogen's but lower than IOL Chemicals'. Additionally, Dishman Carbogen and Aarti Drugs have negative six-month returns.

What does RPG LifeScience. do?

RPG Life Sciences Ltd manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients. As of March 2026, it reported net sales of ₹177 Cr and a net profit of ₹30 Cr, with a market cap of ₹3,502 Cr.

Overview:<BR>RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History:<BR>The company was incorporated in 2007, originally named 'RPG Pharmaceuticals Limited', and it transitioned from its previous identity as Searle India Limited, which began as a joint venture in 1968. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 177 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 30 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 3,502 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 32.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 1.15%<BR>- Debt-Equity: -0.36<BR>- Return on Equity: 18.57%<BR>- Price to Book: 5.72<BR><BR>Contact Details:<BR>Address: RPG House, 463 Dr Annie Besant Road Worli Mumbai Maharashtra : 400030<BR>Tel: 91-022-24981650<BR>Email: info@rpglifesciences.com<BR>Website: http://www.rpglifesciences.com

Is RPG LifeScience. technically bullish or bearish?

As of December 3, 2025, the technical trend for RPG LifeScience has shifted to mildly bearish, influenced by bearish signals from the MACD, KST, and Bollinger Bands, despite a mildly bullish daily moving average.

As of 3 December 2025, the technical trend has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly chart and mildly bearish on the monthly chart, while the KST also shows bearish signals on both time frames. The Dow Theory indicates a mildly bearish stance for both weekly and monthly periods. Although the daily moving averages show a mildly bullish trend, the overall sentiment is dampened by the bearish signals from the Bollinger Bands on the weekly chart and the mildly bearish OBV on the weekly chart. The RSI shows no signals on both weekly and monthly time frames, indicating a lack of momentum. Overall, the combination of these indicators suggests a cautious outlook for RPG LifeScience in the near term.

Is RPG LifeScience. overvalued or undervalued?

As of November 7, 2025, RPG LifeScience is fairly valued with a PE Ratio of 35.54, strong operational efficiency indicated by a ROCE of 46.94% and ROE of 21.01%, and has outperformed the Sensex over the last three and five years, making it an attractive investment compared to its peers.

As of 7 November 2025, the valuation grade for RPG LifeScience has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 35.54, an EV to EBITDA of 24.78, and a PEG Ratio of 0.84, indicating a relatively attractive growth potential compared to its price.<BR><BR>In comparison to its peers, RPG LifeScience's PE Ratio is slightly higher than Sun Pharma's 35.17 but significantly lower than Divi's Lab's 71.11, which is categorized as very expensive. Additionally, while Cipla is rated as attractive with a PE of 22.33, RPG LifeScience's strong ROCE of 46.94% and ROE of 21.01% suggest robust operational efficiency. Notably, RPG LifeScience has outperformed the Sensex over the last three and five years, with returns of 174.55% and 559.32%, respectively, reinforcing its competitive position in the market.

How has been the historical performance of RPG LifeScience.?

RPG LifeScience has shown consistent growth in net sales and profits, with net sales rising from 330.16 Cr in March 2019 to 653.43 Cr in March 2025, and profit after tax increasing from 10.81 Cr to 183.24 Cr in the same period, reflecting strong financial performance and enhanced shareholder value.

Answer:<BR>The historical performance of RPG LifeScience shows a consistent growth trajectory in net sales and profits over the years. <BR><BR>Breakdown:<BR>RPG LifeScience's net sales have increased from 330.16 Cr in March 2019 to 653.43 Cr in March 2025, reflecting a strong upward trend. The total operating income has followed the same pattern, rising from 330.16 Cr in March 2019 to 653.43 Cr in March 2025. The company's operating profit, excluding other income, has also seen significant growth, climbing from 33.56 Cr in March 2019 to 159.65 Cr in March 2025. This is complemented by an increase in profit before tax, which surged from 15.05 Cr in March 2019 to 232.88 Cr in March 2025. The profit after tax has similarly escalated from 10.81 Cr in March 2019 to 183.24 Cr in March 2025, indicating improved profitability. The earnings per share have dramatically increased from 6.54 in March 2019 to 110.8 in March 2025, showcasing enhanced shareholder value. Overall, RPG LifeScience has demonstrated robust financial performance with increasing revenues and profits over the years.

Who are the top shareholders of the RPG LifeScience.?

The top shareholders of RPG LifeScience include Nucleus Life Trust with 53.94%, Authum Investment And Infrastructure Limited at 2.02%, and individual investors holding 15.33%. Additionally, mutual funds hold 3.53%, and 46 foreign institutional investors have a combined stake of 1.45%, with no pledged promoter holdings reported.

The top shareholders of RPG LifeScience include the promoters, with Nucleus Life Trust, managed by Mr. Harsh Vardhan Goenka as a trustee, holding the largest stake at 53.94%. Other significant shareholders include Authum Investment And Infrastructure Limited, which holds 2.02%, and individual investors collectively owning 15.33%. Additionally, the company has mutual funds represented by six schemes, holding 3.53%, and 46 foreign institutional investors (FIIs) with a combined holding of 1.45%. There are no pledged promoter holdings reported.

Has RPG LifeScience. declared dividend?

RPG Life Sciences Ltd has declared a 200% dividend, amounting to ₹16 per share, with an ex-date of June 28, 2024. The company has shown significant total returns over various periods, particularly in the long term, despite a recent short-term decline.

RPG Life Sciences Ltd has declared a 200% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 200%<BR>- Amount per share: 16<BR>- Ex-date: 28 Jun 24<BR><BR>Dividend Yield: 0.74%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.98%, with a dividend return of 0%, resulting in a total return of -2.98%.<BR><BR>Over the past year, the price return was 47.74%, the dividend return was 1.03%, leading to a total return of 48.77%.<BR><BR>In the 2-year period, the price return was 168.65%, the dividend return was 3.07%, culminating in a total return of 171.72%.<BR><BR>For the 3-year period, the price return was 316.33%, with a dividend return of 7.27%, resulting in a total return of 323.6%.<BR><BR>In the last 4 years, the price return was 388.09%, the dividend return was 9.96%, giving a total return of 398.05%.<BR><BR>Over the past 5 years, the price return was 661.83%, with a dividend return of 16.67%, leading to a total return of 678.5%.<BR><BR>Overall, RPG Life Sciences Ltd has declared a substantial dividend, and the total returns over various periods reflect significant growth, particularly in the longer term, despite a recent decline in the short-term price return.